Core Insights - Enlivex Therapeutics Ltd. is hosting a live investor webinar on March 5, 2025, to discuss positive interim six-month data from its Phase I/II Allocetra™ trial for knee osteoarthritis [1][4] Group 1: Trial Results - The interim results from the Allocetra™ trial showed a statistically significant 47.0% average reduction in reported pain (P=0.0001) and a 46% improvement in joint function at six months post-treatment [2] - 83% of treated patients were still considered responders to treatment at six months, indicating the durability and sustained efficacy of Allocetra™ [2][3] - No serious adverse events were reported, reinforcing the favorable safety profile of Allocetra™ [2] Group 2: Company Commitment - The CEO of Enlivex expressed excitement about the promising interim results, highlighting Allocetra™'s potential to provide meaningful and sustained pain relief for patients with moderate to severe knee osteoarthritis [3] - The company remains committed to advancing this innovative therapy to unlock its full potential for millions of patients worldwide [3] Group 3: Webinar Details - The webinar will feature a detailed review of the interim results and will include a live Q&A session [4] - Interested investors can register for the free webinar through the provided link [4]
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis